Using a machine learning software platform (AMPLY) to solve the global animal health problem of Bovine Mastitis through use of novel, patentable, antimicrobial peptides

Amply是贝尔法斯特女王大学的一个抗菌产品发现副产品，它使用创新的机器学习和人工智能方法来挖掘巨大的生物数据集，寻找新的生物活性多肽。Amply专注于动物保健市场，寻找影响畜牧业和全球食物链的复杂疾病的答案。该项目验证了使用Amply技术开采的候选抗菌肽，这些抗菌肽具有解决牛乳腺炎(BM)的全球问题的潜力，BM是一种由于细菌感染而导致的奶牛乳房组织的持续性炎症反应。根据农业和园艺发展局的说法，英国“乳房炎的治疗和控制是英国乳制品行业最大的成本之一，也是奶牛福利的一个重要因素”。BM影响牛奶产量和质量。预计到2023年，该市场将达到14.4亿美元。据估计，全球每年BM的医疗负担可能达到300亿美元。目前BM治疗方法产生的一个必然问题是抗菌素耐药性的影响，这是全球十大公共卫生威胁之一。AMPLY正在使用人工智能更快地生产新药候选药物，降低药物开发的风险，并在保护人类食物链的同时为畜牧业创造解决方案。

AMPLY is an antimicrobial product discovery spin-out from the Queen's University of Belfast which employs innovative machine learning and AI methods to mine huge biological datasets searching for novel bioactive peptides. AMPLY focuses on the animal health market searching for answers to complex diseases which affect the livestock industry and the global food chain.This project validates candidate antimicrobial peptides, mined using AMPLY's technology, which have the potential to solve the global problem of Bovine Mastitis (BM), a persistent, inflammatory reaction of a cow's udder tissue due to bacterial infection. According to the Agriculture and Horticulture Development Board, UK "_Mastitis treatment and control is one of the largest costs to the GB dairy industry and is a significant factor in dairy cow welfare_". BM impacts milk production and quality. The market is predicted to reach $1.44 billion by 2023\.Estimates show healthcare burden globally of BM may be $30 billion annually. A corollary issue arising from current treatments for BM is the impact of antimicrobial resistance, a top 10 global public health threat.AMPLY is using AI to produce new drug candidates more quickly, de-risking drug development, and creating solutions for the livestock industry while safeguarding humanity's food chain.